The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts
Open accessAbstract
Levodopa‐induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa‐to‐dopamine conversion in serotonergic neurons, hyperactivity of corticostriatal glutamatergic transmission, and overstimulation of nicotinic acetylcholine receptors on dopamine‐releasing axons. Delay in initiating levodopa is no longer recommended, as dyskinesia development is a function of disease duration rather than cumulative levodopa exposure. We review current and in‐development treatments for peak‐dose dyskinesia but suggest that improvements in levodopa delivery alone may reduce its future prevalence. Ann Neurol 2018;84:797–811
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,454
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Self-citationDirect and indirect pathways of basal ganglia: a critical reappraisal
Calabresi, P., Picconi, B., Tozzi, A., Ghiglieri, V., & Di Filippo, M. (2014) · Nature Neuroscience · doi:10.1038/nn.3743 · Cited by 828
Self-citationLoss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., & Calabresi, P. (2003) · Nature Neuroscience · doi:10.1038/nn1040 · Cited by 821 · cited 1×
“cade downstream of the D1 dopamine receptors leading to an increase in DARPP32 phosphorylation.(45) A spike-timing–dependent protocol has revealed that the homeostatic adaptation in intrinsic excitability of spiny neurons is lost in mice with LID, suggesting an alteration of the number of corticostriatal synapses(46)…”
BackgroundSelf-citationFunctional and pathophysiological models of the basal ganglia
Wichmann, T., & DeLong, M. R. (1996) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(96)80024-9 · Cited by 731
Olanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., Vanagunas, A., Othman, A. A., Widnell, K. L., Robieson, W. Z., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70293-x · Cited by 716
Self-citationDopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats
Carta, M., Carlsson, T., Kirik, D., & Bjorklund, A. (2007) · Brain · doi:10.1093/brain/awm082 · Cited by 636
Fox, S. H., Katzenschlager, R., Lim, S., Ravina, B., Seppi, K., Coelho, M., Poewe, W., Rascol, O., Goetz, C. G., & Sampaio, C. (2011) · Movement Disorders · doi:10.1002/mds.23829 · Cited by 523
Self-citationWarren Olanow, C., Kieburtz, K., Rascol, O., Poewe, W., Schapira, A. H., Emre, M., Nissinen, H., Leinonen, M., Stocchi, F., & Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) Investigators (2013) · Movement Disorders · doi:10.1002/mds.25364 · Cited by 484
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Self-citationTreatment of motor and non-motor features of Parkinson's disease with deep brain stimulation
Fasano, A., Daniele, A., & Albanese, A. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70049-2 · Cited by 437
Self-citationPD MED Collaborative Group (2014) · The Lancet · doi:10.1016/s0140-6736(14)60683-8 · Cited by 407
de la Fuente-Fernandez, R. (2004) · Brain · doi:10.1093/brain/awh290 · Cited by 402
Pavón, N., Martín, A. B., Mendialdua, A., & Moratalla, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.044 · Cited by 341
Cilia, R., Akpalu, A., Sarfo, F. S., Cham, M., Amboni, M., Cereda, E., Fabbri, M., Adjei, P., Akassi, J., Bonetti, A., et al. (2014) · Brain · doi:10.1093/brain/awu195 · Cited by 339
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias
Morgante, F., Espay, A. J., Gunraj, C., Lang, A. E., & Chen, R. (2006) · Brain · doi:10.1093/brain/awl031 · Cited by 327
Self-citationThe Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
Self-citationSwann, N. C., de Hemptinne, C., Miocinovic, S., Qasim, S., Wang, S. S., Ziman, N., Ostrem, J. L., San Luciano, M., Galifianakis, N. B., & Starr, P. A. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1128-16.2016 · Cited by 322
Tanaka, H., Kannari, K., Maeda, T., Tomiyama, M., Suda, T., & Matsunaga, M. (1999) · NeuroReport · doi:10.1097/00001756-199902250-00034 · Cited by 302
Fieblinger, T., Graves, S. M., Sebel, L. E., Alcacer, C., Plotkin, J. L., Gertler, T. S., Chan, C. S., Heiman, M., Greengard, P., Cenci, M. A., et al. (2014) · Nature Communications · doi:10.1038/ncomms6316 · Cited by 295
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD
Katzenschlager, R., Head, J., Schrag, A., Ben-Shlomo, Y., Evans, A., & Lees, A. J. (2008) · Neurology · doi:10.1212/01.wnl.0000310812.43352.66 · Cited by 271
A Critical Interaction between NR2B and MAGUK in l-DOPA Induced Dyskinesia
Gardoni, F., Picconi, B., Ghiglieri, V., Polli, F., Bagetta, V., Bernardi, G., Cattabeni, F., Di Luca, M., & Calabresi, P. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5326-05.2006 · Cited by 269
Self-citationGoetz, C. G., Damier, P., Hicking, C., Laska, E., Müller, T., Olanow, C. W., Rascol, O., & Russ, H. (2007) · Movement Disorders · doi:10.1002/mds.21226 · Cited by 260
Adaptive deep brain stimulation in a freely moving parkinsonian patient
Rosa, M., Arlotti, M., Ardolino, G., Cogiamanian, F., Marceglia, S., Di Fonzo, A., Cortese, F., Rampini, P. M., & Priori, A. (2015) · Movement Disorders · doi:10.1002/mds.26241 · Cited by 255
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients
Politis, M., Wu, K., Loane, C., Brooks, D. J., Kiferle, L., Turkheimer, F. E., Bain, P., Molloy, S., & Piccini, P. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71640 · Cited by 244
Shen, W., Plotkin, J. L., Francardo, V., Ko, W. K. D., Xie, Z., Li, Q., Fieblinger, T., Wess, J., Neubig, R. R., Lindsley, C. W., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.10.039 · Cited by 244
Self-citationKrack, P. (1999) · Brain · doi:10.1093/brain/122.6.1133 · Cited by 229
Clozapine improves dyskinesias in Parkinson disease: A double-blind, placebo-controlled study
Durif, F., Debilly, B., Galitzky, M., Morand, D., Viallet, F., Borg, M., Thobois, S., Broussolle, E., & Rascol, O. (2004) · Neurology · doi:10.1212/01.wnl.0000110317.52453.6c · Cited by 224
Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias
Ahmed, I., Bose, S. K., Pavese, N., Ramlackhansingh, A., Turkheimer, F., Hotton, G., Hammers, A., & Brooks, D. J. (2011) · Brain · doi:10.1093/brain/awr028 · Cited by 212
Reciprocal Regulation of Dopamine D1 and D3 Receptor Function and Trafficking by Heterodimerization
Fiorentini, C., Busi, C., Gorruso, E., Gotti, C., Spano, P., & Missale, C. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.043885 · Cited by 210
van der Stelt, M., Fox, S. H., Hill, M., Crossman, A. R., Petrosino, S., Di Marzo, V., & Brotchie, J. M. (2005) · The FASEB Journal · doi:10.1096/fj.04-3010fje · Cited by 199
Self-citationMorgese, M. G., Cassano, T., Cuomo, V., & Giuffrida, A. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.021 · Cited by 196
Carlsson, T., Carta, M., Winkler, C., Björklund, A., & Kirik, D. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2079-07.2007 · Cited by 191
Santini, E., Alcacer, C., Cacciatore, S., Heiman, M., Hervé, D., Greengard, P., Girault, J., Valjent, E., & Fisone, G. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05831.x · Cited by 187
Gerlach, M., Double, K., Arzberger, T., Leblhuber, F., Tatschner, T., & Riederer, P. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0027-5 · Cited by 187
Pahwa, R., Tanner, C. M., Hauser, R. A., Isaacson, S. H., Nausieda, P. A., Truong, D. D., Agarwal, P., Hull, K. L., Lyons, K. E., Johnson, R., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0943 · Cited by 177
A daptive deep brain stimulation controls levodopa‐induced side effects in P arkinsonian patients
Rosa, M., Arlotti, M., Marceglia, S. R. F., Cogiamanian, F. M., Ardolino, G., Fonzo, A. D., Lopiano, L., Scelzo, E., Merola, A., Locatelli, M., et al. (2017) · Movement Disorders · doi:10.1002/mds.26953 · Cited by 167
Self-citationCortical Control of Striatal Dopamine Transmission via Striatal Cholinergic Interneurons
Kosillo, P., Zhang, Y.-F., Threlfell, S., & Cragg, S. J. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhw252 · Cited by 164
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
Svenningsson, P., Rosenblad, C., af Edholm Arvidsson, K., Wictorin, K., Keywood, C., Shankar, B., Lowe, D. A., Björklund, A., & Widner, H. (2015) · Brain · doi:10.1093/brain/awu409 · Cited by 162
Alcacer, C., Andreoli, L., Sebastianutto, I., Jakobsson, J., Fieblinger, T., & Cenci, M. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90132 · Cited by 157
Tison, F., Keywood, C., Wakefield, M., Durif, F., Corvol, J., Eggert, K. M., Lew, M., Isaacson, S., Bézard, E., Poli, S.-M., et al. (2016) · Movement Disorders · doi:10.1002/mds.26659 · Cited by 144
Mansouri, A., Taslimi, S., Badhiwala, J. H., Witiw, C. D., Nassiri, F., Odekerken, V. J. J., de Bie, R. M. A., Kalia, S. K., Hodaie, M., Munhoz, R. P., et al. (2017) · Journal of neurosurgery · doi:10.3171/2016.11.jns16715 · Cited by 143
Self-citationAbnormal bidirectional plasticity-like effects in Parkinson's disease
Huang, Y., Rothwell, J. C., Lu, C., Chuang, W.-L., & Chen, R.-S. (2011) · Brain · doi:10.1093/brain/awr158 · Cited by 137
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa‐induced dyskinesia
Bézard, E., Tronci, E., Pioli, E. Y., Li, Q., Porras, G., Björklund, A., & Carta, M. (2013) · Movement Disorders · doi:10.1002/mds.25366 · Cited by 136
Suárez, L. M., Solís, Ó., Aguado, C., Luján, R., & Moratalla, R. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhw263 · Cited by 136
Placebo influences on dyskinesia in Parkinson's disease
Goetz, C. G., LASKA, E. M., Hicking, C., Damier, P., Müller, T. H., Nutt, J. G., Olanow, C. W., Rascol, O., & Russ, H. (2008) · Movement Disorders · doi:10.1002/mds.21897 · Cited by 131
Nadjar, A., Gerfen, C. R., & Bézard, E. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.09.013 · Cited by 129
Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo
Laere, K. V., Casteels, C., Lunskens, S., Goffin, K. E., Grachev, I. D., Bormans, G. M., & Vandenberghe, W. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.009 · Cited by 123
Niccolini, F., Foltynie, T., Marques, T. R., Muhlert, N., Tziortzi, A. C., Searle, G. E., Natesan, S., Kapur, S., Rabiner, E. A., Gunn, R. N., et al. (2015) · Brain · doi:10.1093/brain/awv219 · Cited by 123
Parkinson Study Group (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200001000-00007 · Cited by 119
Cannabinoid–dopamine interactions in the physiology and physiopathology of the basal ganglia
García, C., Palomo‐Garo, C., Gómez‐Gálvez, Y., & Fernández‐Ruíz, J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13215 · Cited by 114
Mura, A., Jackson, D., Manley, M. S., Young, S. J., & Groves, P. M. (1995) · Brain Research · doi:10.1016/0006-8993(95)01104-8 · Cited by 112
Cerasa, A., Koch, G., Donzuso, G., Mangone, G., Morelli, M., Brusa, L., Bassi, M. S., Ponzo, V., Picazio, S., Passamonti, L., et al. (2014) · Brain · doi:10.1093/brain/awu329 · Cited by 111
Sierra, S., Luquin, N., Rico, A. J., Gómez-Bautista, V., Roda, E., Dopeso‐Reyes, I. G., Vázquez, A., Martínez‐Pinilla, E., Labandeira-García, J. L., Franco, R., et al. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0823-8 · Cited by 111
Hyperkinetic disorders and loss of synaptic downscaling
Calabresi, P., Pisani, A., Rothwell, J. C., Ghiglieri, V., Obeso, J. A., & Picconi, B. (2016) · Nature Neuroscience · doi:10.1038/nn.4306 · Cited by 111
Self-citationJones, C. K., Bubser, M., Thompson, A. D., Dickerson, J. W., Turle-Lorenzo, N., Amalric, M., Blobaum, A. L., Bridges, T. M., Morrison, R. D., Jadhav, S. B., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.187443 · Cited by 108
Wood, M. D., Dubois, V., Scheller, D., & Gillard, M. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12988 · Cited by 105
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum
Porras, G., Deurwaerdère, P. D., Li, Q., Marti, M., Morgenstern, R., Sohr, R., Bézard, E., Morari, M., & Meissner, W. G. (2014) · Scientific Reports · doi:10.1038/srep03730 · Cited by 93
Kishore, A., Popa, T., Velayudhan, B., Joseph, T., Balachandran, A., & Meunier, S. (2012) · Brain · doi:10.1093/brain/aws124 · Cited by 93
E ffect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced P arkinson's disease patients
Antonini, A., Fung, V. S. C., Boyd, J. T., Slevin, J. T., Hall, C. M., Chatamra, K., Eaton, S., & Benesh, J. A. (2016) · Movement Disorders · doi:10.1002/mds.26528 · Cited by 93
Mellone, M., Stanic, J., Hernández, L. F., Iglesias, E., Zianni, E., Longhi, A., Prigent, A., Picconi, B., Calabresi, P., Hirsch, É. C., et al. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00245 · Cited by 91
Self-citationThiele, S. L., Chen, B., Lo, C., Gertler, T. S., Warre, R., Surmeier, D. J., Brotchie, J. M., & Nash, J. E. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.006 · Cited by 91
Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias
Bordia, T., Perez, X. A., Heiss, J. E., Zhang, D., & Quik, M. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.02.019 · Cited by 91
Litim, N., Morissette, M., & Paolo, T. D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.036 · Cited by 89
Iderberg, H., McCreary, A. C., Varney, M. A., Kleven, M. S., Koek, W., Bardin, L., Depoortère, R., Cenci, M. A., & Newman‐Tancredi, A. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.05.021 · Cited by 85
Differential genetic susceptibility in diphasic and peak‐dose dyskinesias in Parkinson's disease
Lee, J., Cho, J., Lee, E., Park, S. S., & Jeon, B. S. (2010) · Movement Disorders · doi:10.1002/mds.23400 · Cited by 85
Cerasa, A., Pugliese, P., Messina, D., Morelli, M., Gioia, M. C., Salsone, M., Novellino, F., Nicoletti, G., Arabia, G., & Quattrone, A. (2011) · Movement Disorders · doi:10.1002/mds.24017 · Cited by 83
Herz, D. M., Haagensen, B. N., Christensen, M. S., Madsen, K. H., Rowe, J. B., Løkkegaard, A., & Siebner, H. R. (2015) · Brain · doi:10.1093/brain/awv096 · Cited by 82
Yamamura, Y., Hattori, N., Matsumine, H., Kuzuhara, S., & Mizuno, Y. (2000) · Brain and Development · doi:10.1016/s0387-7604(00)00130-3 · Cited by 82
The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model
Bézard, E., Pioli, E. Y., Li, Q., Girard, F., Mutel, V., Keywood, C., Tison, F., Rascol, O., & Poli, S. M. (2014) · Movement Disorders · doi:10.1002/mds.25920 · Cited by 81
Serotonin-to-dopamine transporter ratios in Parkinson disease
Roussakis, A., Politis, M., Towey, D., & Piccini, P. P. (2016) · Neurology · doi:10.1212/wnl.0000000000002494 · Cited by 79
Cerasa, A., Morelli, M., Augimeri, A., Salsone, M., Novellino, F., Gioia, M. C., Arabia, G., & Quattrone, A. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.06.003 · Cited by 74
The acute brain response to levodopa heralds dyskinesias in Parkinson disease
Herz, D. M., Haagensen, B. N., Christensen, M. S., Madsen, K. H., Rowe, J. B., Løkkegaard, A., & Siebner, H. R. (2014) · Annals of Neurology · doi:10.1002/ana.24138 · Cited by 74
R esting‐state connectivity predicts levodopa‐induced dyskinesias in P arkinson's disease
Herz, D. M., Haagensen, B. N., Nielsen, S. H., Madsen, K. H., Løkkegaard, A., & Siebner, H. R. (2016) · Movement Disorders · doi:10.1002/mds.26540 · Cited by 73
Espay, A. J., & Lang, A. E. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0348 · Cited by 72
Self-citationNovel Levodopa Formulations for Parkinson’s Disease
Freitas, M. E., Ruíz-López, M., & Fox, S. H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0386-8 · Cited by 69
Self-citationD1receptor blockade improves l -dopa–induced dyskinesia but worsens parkinsonism in MPTP monkeys
Grondin, R., Doan, V. D., Grégoire, L., & Bédard, P. J. (1999) · Neurology · doi:10.1212/wnl.52.4.771 · Cited by 63
Patient perception of dyskinesia in Parkinson's disease
Hung, S., Adeli, G., Arenovich, T., Fox, S. H., & Lang, A. E. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.173286 · Cited by 60
Self-citationPutaminal serotonergic innervation
Lee, J., Seo, S., Lee, J. S., Kim, H., Kim, Y. K., & Jeon, B. S. (2015) · Neurology · doi:10.1212/wnl.0000000000001909 · Cited by 59
A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA –Induced Dyskinesia and ∆FosB Expression
Feyder, M. T., Södersten, E., Santini, E., Vialou, V., LaPlant, Q. C., Watts, E. L., Spigolon, G., Hansen, K. H., Caboche, J., Nestler, E. J., et al. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.07.019 · Cited by 54
Dyskinesia and the antiparkinsonian response always temporally coincide
Nutt, J. G., Chung, K. A., & Holford, N. H. G. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d90050 · Cited by 52
Potts, L. F., Park, E. S., Woo, J., Shetty, B. L. D., Singh, A. P., Braithwaite, S. P., Voronkov, M. V., Papa, S. M., & Mouradian, M. M. (2015) · Annals of Neurology · doi:10.1002/ana.24375 · Cited by 51
Prescott, I. A., Liu, L. D., Dostrovsky, J. O., Hodaie, M., Lozano, A. M., & Hutchison, W. D. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.002 · Cited by 50
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias
Stanic, J., Mellone, M., Napolitano, F., Racca, C., Zianni, E., Minocci, D., Ghiglieri, V., Thiolat, M.-L., Li, Q., Longhi, A., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.08.001 · Cited by 48
Self-citationA Placebo‐Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa‐Induced Dyskinesia
Trenkwalder, C., Berg, D., Rascol, O., Eggert, K. M., Ceballos-Baumann, A., Corvol, J., Storch, A., Zhang, L., Azulay, J., Broussolle, E., et al. (2016) · Movement Disorders · doi:10.1002/mds.26569 · Cited by 44
Self-citationSmith, R., Wu, K., Hart, T., Loane, C., Brooks, D., Björklund, A., Odin, P., Piccini, P., & Politis, M. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.037 · Cited by 43
Enhanced histamine H2 excitation of striatal cholinergic interneurons in l-DOPA-induced dyskinesia
Lim, S. A. O., Xia, R., Ding, Y., Won, L., Ray, W. J., Hitchcock, S. A., McGehee, D. S., & Kang, U. J. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.01.003 · Cited by 43
Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson’s disease
Nicoletti, A. S. Q., Mostile, G., Nicoletti, G., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8075-6 · Cited by 39
The motor inhibition system in Parkinson's disease with levodopa‐induced dyskinesias
Cerasa, A., Donzuso, G., Morelli, M., Mangone, G., Salsone, M., Passamonti, L., Augimeri, A., Arabia, G., & Quattrone, A. (2015) · Movement Disorders · doi:10.1002/mds.26378 · Cited by 38
Trial of dextromethorphan/quinidine to treat levodopa‐induced dyskinesia in Parkinson's disease
Fox, S. H., Metman, L. V., Nutt, J. G., Brodsky, M., Factor, S. A., Lang, A. E., Pope, L. E., Knowles, N., & Siffert, J. O. (2017) · Movement Disorders · doi:10.1002/mds.26976 · Cited by 36
Self-citationElia, A. E., Dollenz, C., Soliveri, P., & Albanese, A. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03437.x · Cited by 35
Bez, F., Francardo, V., & Cenci, M. A. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.06.005 · Cited by 28
Management of Motor Complications in Parkinson Disease: Current and Emerging Therapies
Espay, A. J. (2010) · Neurologic Clinics · doi:10.1016/j.ncl.2010.03.014 · Cited by 21
Self-citationDiphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease
Meloni, M., Solla, P., Mascia, M. M., Marrosu, F., & Cannas, A. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.12.030 · Cited by 21
Samadi, P., Grégoire, L., Tahar, A. H., Paolo, T. D., Rouillard, C., & BEDARD, P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.02.009 · Cited by 14
Cited by
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Parkinson’s disease: etiopathogenesis and treatment
Jankovic, J., & Tan, E. K. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322338 · Cited by 1,169
Rho kinase inhibitor fasudil reduces l‐DOPA‐induced dyskinesia in a rat model of Parkinson's disease
Lopez‐Lopez, A., Labandeira, C. M., Labandeira‐Garcia, J. L., & Muñoz, A. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15275 · Cited by 40
Khan, A. F., Adewale, Q., Lin, S.-J., Baumeister, T. R., Zeighami, Y., Carbonell, F., Palomero-Gallagher, N., & Iturria-Medina, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-41677-w · Cited by 28
Miller, S. J., Darji, R. Y., Walaieh, S., Lewis, J. A., & Logan, R. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1271941 · Cited by 16
Metadata
- Authors
- Espay, A. J., Morgante, F., Merola, A., Fasano, A., Marsili, L., Fox, S. H., Bezard, E., Picconi, B., Calabresi, P., & Lang, A. E.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2018-11-30
- Volume
- 84
- Issue
- 6
- Pages
- 797-811
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2898096496
- Cited by
- 340
- References
- 96
- FWCI
- 18.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.